IVIG Can Cause Fluid Retention and Volume Overload
Yes, IVIG infusion can potentially cause fluid retention and volume overload, particularly because standard dosing (2 g/kg) involves administering large volumes of fluid over 10-12 hours. This is especially concerning in patients with cardiac dysfunction or those at risk for volume overload 1.
Mechanism and Volume Considerations
IVIG is administered as a 5% protein solution, meaning a 70 kg patient receiving the standard 2 g/kg dose would receive approximately 2.8 liters of fluid over the infusion period 2. This substantial fluid load can precipitate or worsen:
- Cardiac dysfunction - particularly problematic in conditions like Kawasaki disease where myocarditis may be present
- Acute heart failure in patients with pre-existing cardiac disease
- Pulmonary edema in volume-sensitive patients
Additional Fluid-Related Risks
Beyond simple volume overload, IVIG causes several related complications:
Hyperproteinemia and Increased Viscosity
- IVIG administration increases serum protein concentration and blood viscosity 1
- This can lead to pseudohyponatremia (falsely low sodium due to hyperproteinemia rather than true dilution) 1
- Increased viscosity contributes to thrombotic risk, independent of volume status 3, 4
Thrombotic Complications
The FDA black box warning emphasizes thrombosis risk, which is partially mediated by:
- Hyperviscosity from the protein load 1
- Volume depletion if diuretics are inappropriately used to manage fluid retention 1
- The combination creates a paradoxical situation where fluid overload and hyperviscosity coexist 3
High-Risk Populations
Patients requiring special caution include 1:
- Those with cardiac dysfunction or heart failure
- Elderly patients (>65 years)
- Patients with renal insufficiency
- Those with pre-existing volume overload
- Patients with hypercoagulable states
Risk Mitigation Strategies
The FDA label and clinical evidence provide specific guidance 1, 5, 6:
Before infusion:
- Ensure adequate baseline hydration (paradoxically, dehydration increases risk)
- Assess cardiac and renal function
- Consider slower infusion rates (maximum 0.10 mL/kg/min or 5 mg/kg/min)
During infusion:
- Monitor for signs of volume overload (dyspnea, edema, weight gain)
- Slow or stop infusion if symptoms develop
- Use minimum effective infusion rate in high-risk patients 5
Special consideration: Recent evidence suggests that in conditions like MIS-C where cardiac dysfunction is common, avoiding IVIG as first-line therapy and using corticosteroids instead may improve outcomes specifically because it avoids the large fluid volume 7.
Clinical Pitfall
Do not treat IVIG-induced pseudohyponatremia with fluid restriction or diuretics 1. This represents hyperproteinemia with falsely low measured sodium, not true hyponatremia. Aggressive diuresis will worsen hyperviscosity and dramatically increase thrombotic risk. Distinguish this from true hyponatremia by checking serum osmolality and osmolar gap.
Renal Considerations
IVIG can cause acute renal failure through osmotic injury (especially with sucrose-containing products) 1, 3. Monitor:
- Urine output during and after infusion
- BUN and creatinine before and after treatment
- Consider discontinuation if renal function deteriorates
The combination of potential volume overload, hyperviscosity, and renal dysfunction makes IVIG a high-risk infusion requiring careful patient selection, adequate hydration, slow administration, and close monitoring 6, 3.